EGFR and non-small cell lung carcinoma: However, most clinical trials have failed to demonstrate the benefit of EGFR-targeted therapies in gliomas, as approved EGFR therapies have mainly focused on NSCLC EGFR gene alterations that are, however, distinct from those driving gliomagenesis (Lin et al., 2022).